Reach 90% of Germany’s key payers at once – Introducing our exclusive newsletter channel
May 12, 2025
With our unique newsletter format, you have access to approximately 90% of the drug experts working within Germany’s healthcare institutions. These professionals are responsible for evaluating, recommending, and shaping decisions on drug usage across hospitals, clinics, and public healthcare systems.
Supporting Early Market Access Success
In Germany, following EMA approval, pharmaceutical products can be prescribed immediately. However, within the first 12 months of market entry, manufacturers must demonstrate the therapeutic value of their products as part of the AMNOG process.
Engaging healthcare stakeholders early – building awareness, encouraging adoption, and gathering real-world insights – is critical during this decisive period.
Our communication channel helps increase visibility and supports early engagement with the healthcare environment. This creates valuable opportunities to build clinical confidence, collect feedback, and position your product ahead of formal benefit assessments and pricing negotiations.
By partnering with us, you enhance your ability to generate early adoption data and support a successful market access strategy in Germany.
Our offer:
A dedicated media channel exclusively targeting verified drug experts — no broad or unfocused distribution.
Efficient communication via a trusted healthcare media outlet read by professionals who influence prescribing and reimbursement discussions.
A well-established, recognized format developed and edited by a former senior payer.
Our newsletter strategy is part of a broader suite of services designed to help you gain a strong foothold in the German healthcare sector. In addition to targeted communications, we support clients in developing access strategies, shaping compelling value propositions, and building a solid foundation for success in Germany.
This exclusive communication format is an ideal first step to drive early engagement, build credibility, and gather insights ahead of benefit assessments and reimbursement negotiations.
How does it work?
Whenever there’s a relevant update, we create a focused, professional communication.
This newsletter is distributed via an established healthcare media platform — regularly read by stakeholders in hospitals, outpatient settings, and payer organizations. Your message becomes part of the trusted information ecosystem that informs key actors in the German healthcare system.
If you're preparing to bring a new product to market or want to raise awareness among those shaping drug policy and prescribing frameworks in Germany, this channel offers a credible and strategic starting point.
Contact us to explore how we can support your market ambitions in Germany.